

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 20784/4-CON		SERIAL NO. Not yet assigned	
				APPLICANT(S): Demuth et al.			
				FILING DATE: December 11, 2003		ART UNIT: Not yet assigned	
UNITED STATES PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	INVENTOR	CLASS	SUB CLASS	FIL. DATE IF APPR
1	AA	2,961,377	11/22/1960	Shapiro et al.	167	65	
	AB	3,174,901	03/23/1965	Sterne	167	65	
	AC	3,879,541	04/22/1975	Kabbe et al.	424	326	
	AD	3,960,949	06/01/1976	Ahrens et al.	260	564 B	
	AE	4,028,402	06/07/1977	Fischer et al.	260	501.14	
	AF	4,935,493	06/19/1990	Bachovchin et al.	530	331	
	AG	5,433,955	07/18/1995	Bredehorst et al.	424	94.3	
	AH	5,462,928	10/31/1995	Bachovchin et al.	514	19	
	AI	5,512,549	04/30/1996	Chen et al.	514	12	
	AJ	5,543,396	08/06/1996	Powers et al.	514	19	
	AK	5,614,379	03/25/1997	MacKellar	435	68.1	
	AL	5,624,894	04/29/1997	Bodor	514	2	
	AM	5,939,560	08/17/1999	Jenkins et al.	548	535	
	AN	6,006,753	12/28/1999	Efendic	128	898	
	AO	5,827,898	10/27/1998	Khandwala et al.	514	734	
	AP	6,201,132 B1	03/13/2001	Jenkins et al.	548	535	04/21/99
	AQ	6,303,661 B1	10/16/2001	Demuth et al.	514	866	04/24/97
	AR	6,500,804 B2	12/31/2002	Demuth et al.	514	19	12/31/02
	AS	6,319,893 B1	11/20/2001	Demuth et al.	514	2	11/20/01
	AT	6,011,155	01/04/2000	Villhauer	544	333	
	AU	6,107,317	08/22/2000	Villhauer	514	365	
	AV	6,110,949	08/29/2000	Villhauer	514	365	
	AW	6,124,305	09/26/2000	Villhauer	514	272	
2	AX	6,172,081	01/09/2001	Damon	514	307	
Examiner:					Date: 3-20-06		

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 20784/4-CON		SERIAL NO. Not yet assigned	
				APPLICANT(S): Demuth et al.			
				FILING DATE: December 11, 2003		ART UNIT: Not yet assigned	
UNITED STATES PATENT DOCUMENTS							
D	AY	5,705,483	01/06/1998	Galloway et al.	514	12	
J	AZ	2001/0025023 A1	09/27/2001	Carr	514	2	
D	AAA	6,548,481 B1	04/15/2003	Demuth et al.	514	19	11/28/00
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N
D	BA	WO 01/62266 A2	08/30/2001	PCT	A61K	38/00	Y
	BB	WO 00/53171	09/14/2000	PCT	A61K	31/155	Y
	BC	DT 25 42 598 A1	04/22/1976	Germany	C07C	129/16	N
	BD	FR 2 696 740 A1	04/15/1994	France	C07D	207/404	N
	BE	FR 2 085 665	12/31/1971	France	A61K	27/00	N
	BF	WO 97/40832	11/06/1997	PCT	A61K	31/425	Abstract only
	BG	WO 95/15309	06/08/1995	PCT	C07D	207/16	Y
	BH	JP 4334357	11/20/1992	Japan	C07C	233/57	Abstract only
	BI	WO 93/08259	04/29/1993	PCT	C12N		Y
	BJ	WO 95/11689	05/04/1995	PCT	A61K	37/00	Y
	BK	WO 97/45117	12/04/1997	PCT	A61K	31/435	Y
	BL	DE 196 16 486 C2	10/30/1997	Germany	A61K	45/00	Y
	BM	WO 95/29691	11/09/1995	PCT	A61K	38/00	Y
	BN	WO 98/22494	05/28/1998	PCT	C07K	5/06	Y
	BO	WO 00/01849	01/13/2000	PCT	C12Q	1/68	Y
	BP	EP 0 658 568 A1	06/21/1995	EPO	C07K	14/605	Y
	BQ	DD 296 075 A5	11/21/1991	Germany	C07D	295/04	Y
	BR	DD 296 075 A5	11/21/1991	Germany	C07D	295/04	N
D	BS	EP 0 708 179 A2	04/24/1996	EPO	C12N	15/16	Y
Examiner:				Date: 3-20-08			

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTY. DOCKET NO. 20784/4-CON		SERIAL NO. Not yet assigned			
				APPLICANT(S): Demuth et al.					
				FILING DATE: December 11, 2003		ART UNIT: Not yet assigned			
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRAN Y/N		
BT		EP 0 995 440 A1	04/26/2000	EPO	A61K	31/425	N		
BU		WO 91/11457	08/08/1991	PCT	C07K	7/34	Y		
BV		WO 91/16339	10/31/1991	PCT	C07K	5/10	Y		
BW		WO 98/19998	05/14/1998	PCT	C07D	207/00	Y		
BX		WO 91/17767	11/28/1991	PCT	A61K	37/54	Y		
BY		JP 04-288098	10/13/1992	JP	A61K	37/64	(Abstract Only)		
BZ		WO 99/46272 A	09/16/1999	PCT	C07F	9/572	Y		
BAA		DE 299 09 210 U	09/09/1999	Germany	A61K	31/425	N		
BAB		DE 198 26 972 A1	12/23/1999	Germany	A61K	38/05	N		
BAC		WO 01/97808	12/27/2001	PCT	A61K	31/425	Y		
BAD		WO 01/34594 A1	05/17/2001	PCT	C07D	401/06	Y		
BAE		WO 00/10549	03/02/2000	PCT	A61K	31/00	Y		
BAF		WO 01/74299 A2	10/11/2001	PCT	A61K		Y		
BAG		WO 02/20825 A1	03/14/2002	PCT	C12Q	1/00	Y		
BAH		WO 01/89569 A1	11/29/2001	PCT	A61K	45/06	Y		
BAI		WO 99/62914	12/09/1999	PCT	C07F	5/02	Y		
BAJ		WO 99/61431	12/02/1999	PCT	C07D	277/04	Abstract Only-		
BAK		EP 1 130 022 A1	09/15/2001	EPO	C07D	498/09	Y		
BAL		WO 01/32624 A1	05/10/2001	PCT	C07D	217/04	Y		
BAM		WO 01/09169 A2	02/08/2001	PCT	C07K	5/062	Y		
BAN		WO 01/94310 A1	12/13/2001	PCT	C07D	209/12	Y		

Examiner:

Date:

3-20-06


FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/4-CON	SERIAL NO. N t yet assigned
		APPLICANT(S): Demuth et al.	
		FILING DATE: December 11, 2003	ART UNIT: Not yet assigned
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
P	CA	Campbell, I.W. <u>New Antidiabetic Drugs</u> , ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, "Sulphonylureas and merformin: efficacy and inadequacy". 3:33-51 (1990).	
	CB	<u>CHEMICAL ABSTRACTS</u> , vol. 115, No. 15, 14. October 1991 (1991-10-14) Columbus, Ohio, US; abstract no. 149947q, SCHOEN EKKEHARD ET AL: "Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes"	
	CC	<u>CHEMICAL ABSTRACTS</u> , vol. 118, no. 25, 21. June 1993 (1993-06-21) Columbus, Ohio, US; abstract no. 255342k, Hosoda, et al, "Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs as Prolyl Endopeptidase Inhibitors", November 1992 (1992-11-20)	
	CD	<u>CHEMICAL ABSTRACTS</u> , vol. 126, no. 2, 13. January 1997 (1997-01-13) Columbus, Ohio, US; abstract no. 16161j, STOECKEL A. ET AL: "Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides".	
	CE	<u>Martindale The Extra Pharmacopoeia</u> , 30 th Edition, London Pharmaceutical Press, 1993, Page 1619.	
	CF	AMASHEH, S., et al., "Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed in <i>Xenopus Laevis</i> oocytes". <u>J. Physiol.</u> 504, 169-174 (1997)	
	CG	Arai ET AL., "Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain" <u>CHEMICAL AND PHARMACEUTICAL BULLETIN.</u> , Bd. 41, No. 9, 1993, pages. 1583-1588.	
	CH	DURINX, C.; et al.; "Reference Values for Plasma Dipeptidyl-Pepidase IV activity and their Association with Other Laboratory Parameters". <u>Clin Chem Lab Med</u> 2001, February; 39 (2) :155-9, 1 page.	
	CI	GOSSRAU, R.; "Cytochemistry of Membrane Proteases". <u>Histochem J.</u> 1985, July; 17 (7) :737-71, 1 page.	
	CJ	HAHN, T.; et al.; "Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Human First Trimester Placentae". <u>Acta Histochem</u> 1993, December, 95 (2) :185-92, 1 page.	
	CK	HEYMANN, E. et al., "Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation." <u>Klin Wochenschr.</u> 1984, January, 2;62 (1) :2-10, 1 page.	
	CL	Lin, J. et al.: "Inhibition of depeptidyl peptidase IV by fluoroolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics" <u>PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA</u> , Vol. 95, November 1998, pages 14020-14024.	
	CM	KOROM, S., et al "Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients", <u>Transplantation</u> , Vol. 63, 1495 - 1500 No. 10 (1997).	
	CN	MAGYAR, C.E. et al., "Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension." <u>Am J. Physiol Renal Physiol</u> , 2000, August; 279 (2) :F358-69, 1 page.	
C	CO	<u>Martindale The Extra Pharmacopoeia</u> , 30 th Edition, London Pharmaceutical Press, 1993, Page 36.	
Examiner:		Date: 3-20-06	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/4-CON	SERIAL NO. Not yet assigned
		APPLICANT(S): Demuth et al.	
		FILING DATE: December 11, 2003	ART UNIT: Not yet assigned
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
6	CP	MENTLEIN, R., et al., "Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV". <u>Regul. Pept.</u> 49, 133 -144 (1993)	
	CQ	PAPIES, B. et al., "Isoenzyme (Lactate Dehydrogenase, Aspartate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension." <u>Cor Vasa</u> , 1991; 33 (3) :218-26, 1 page.	
	CR	QURESHI, N.U.; et al., "Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock". <u>Regul. Pept.</u> 1998, September 25; 75-76:215-20, 1 page.	
	CS	TANKA, S., et al., "Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV". <u>Int. J. Immunopharmacol.</u> Vol. 19, No. 1 Pages 15-24, (1997)	
	CT	The Merck Index, 11 th Edition, <u>An Encyclopedia of Chemicals, Drugs, and Biologicals</u> , 1989, Page 934	
	CU	The Merck Index, 12 th Edition, <u>An Encyclopedia of Chemicals, Drugs, and Biologicals</u> , 1996, Page 1014.	
	CV	Deacon et al., <u>Journal of Clinical Endocrinology and Metabolism</u> , "Degradation of Glucagon-Like Peptide-1 by Human Plasma in Vitro Yields and N-Terminally Truncated Peptide That Is a Major Endogenous Metabolite in Vivo", (1995), 80(3): 952-957.	
	CW	G.G. Duncan, <u>Diseases of Metabolism (Asian edition)</u> , "Diabetes Mellitus", (1966), p 951-957.	
	CX	Gutniak et al., <u>Diabetes Care</u> , "Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM", September 1994, 17(9): 1039-1044.	
	CY	Gutniak et al., <u>New England Journal of Medicine</u> , "Antidiabetogenic Effect of Glucagon-like peptide-1 (7-36) Amide in Normal Subjects and Patients With Diabetes Mellitus", 1992, 326: 1316-1322.	
	CZ	H.A. Smith et al., <u>Veterinary Pathology</u> (fourth edition), "Diseases and Disorders of Metabolism: Deficiency Diseases", (1972), p 1018-1020.	
	CAA	Hendrick et al., <u>Metabolism - Clinical and Experimental</u> , "Glucagon-like Peptide-I-(7-37) Suppresses Hyperglycemia in Rats", January 1993, 42(1): 1-6.	
	CAB	Hoffmann et al., <u>Journal of Chromatography A</u> , "Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary electrophoresis", 1995, 716:355-362.	
	CAC	Index Nominum, <u>International Drug Directory 1992/1993</u> , Medpharm Scientific Publishers, pages 728-729.	
	CAD	Mannucci et al., <u>Diabetes Care</u> , "Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects", 24(3): 489-494, March 2001.	
	CAE	Nauck et al., <u>Diabetologia</u> , "Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients", (1993), 36: 741-744.	
7	CAF	Pauly et al., <u>Regulatory Peptides</u> , "Abstracts Issue: Abstracts from the 11 th International Symposium on Regulatory Peptides", July 15, 1996, 64(1-3): 148 plus cover.	
Examiner:		Date: 3-20-06	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/4-CON	SERIAL NO. Not yet assigned
		APPLICANT(S): Demuth et al.	
		FILING DATE: December 11, 2003	ART UNIT: Not yet assigned
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
G	CAG	Stryer, <u>Biochemistry 3rd Ed.</u> , "Protein Conformation, Dynamics, and Function", 1988, p 191-193.	
	CAH	T.J. Kieffer et al., "Degradation of Glucose-Dependent Insulinotropic Polypeptide and Truncated Glucagon-Like Peptide 1 In Vitro and In Vivo by DP IV", <u>Endocrinology</u> , Vol. 136(8), (1995), p 3585-3596.	
	CAI	The Merck Index, <u>An Encyclopedia of Chemicals and Drugs</u> , 9 th Edition, Merck & Co., Inc., 1976, page 773	
	CAJ	C.B. Welch, <u>Medical Management of Non-Insulin-Dependent (Type II) Diabetes</u> , 3 rd edition, American Diabetes Association, "Diagnosis and Classification" p. 3, 1994, Pharmacologic Intervention (2 pages).	
	CAK	WETZEL, W., et al., "Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes". <u>Neuropeptides</u> , 31, 41- 45 (1997)	
	CAL	Willms et al., <u>Journal of Clinical Endocrinology Metabolism</u> , "Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients", 1996, 81(1): 327-332.	
	CAM	Ashworth et al., <u>BIOORG. MED. CHEM. LETT.</u> , "2-Cyanopyrrolidides as Potent, Stable Inhibitors of Dipeptidyl Peptidase IV", (1996), 6(10): 1163-1166.	
	CAN	Badia-Elder N.E. et al., <u>Alcoholism Clinical and Experimental Research</u> , "Effects of Neuropeptide Y (NPY) on Ethanol Intake and Anxiety in High and Low Alcohol Drinking (HAD1/LAD1) Rats", (2000), 24(5): 82A.	
	CAO	C.F. Deacon et al., <u>Diabetes</u> , "Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded from the NH ₂ -Terminus in Type II Diabetic Patients and in Healthy Subjects", September 1995, 44: 1126-1131.	
	CAP	Edwards, J.V. et al., <u>J. Peptide Res.</u> , "Synthesis and Activity of NH ₂ - and COOH-Terminal Elastase Recognition Sequences on Cotton," (1999), 54: 536-543.	
	CAQ	Endroczi et al., <u>ACTA PHYSIOL. HUNG.</u> , "Dipeptidyl peptidase IV (DP IV) and Superoxide Dismutase Activity in Thymus-Derived Lymphocytes: Effects of Inhibitory Peptides and Zn ²⁺ in Vitro", (1990), 75(1): 35-44.	
	CAR	Frohman et al., <u>Journal of Clin. Invest.</u> , "Rapid Enzymatic Degradation of Growth Hormone-releasing Hormone by Plasma in Vitro and in Vivo to a Biologically Inactive Product Cleaved at the NH ₂ Terminus", Volume 78, October 1986, p 906-913	
	CAS	<u>Goodman & Gilman's The Pharmacological Basis of Therapeutics</u> , Ninth Edition, (1996), p. 1510.	
	CAT	Hyun Sook Lee et al., "Cathepsin B Inhibitory Peptides Derived from β -Casein," <u>Peptides</u> 21 (2000) 807-809.	
	CAU	Nathan et al., <u>Diabetes Care</u> , "Insulinotropic Action of Glucagonlike Peptide-1-(7-37) in Diabetic and Nondiabetic Subjects", February 1992, 15(2): 270-275.	
	CAV	Pauly et al., <u>Metabolism</u> , "Improved Glucose Tolerance in Rats Treated with the Dipeptidyl Peptidase IV (CD26) Inhibitor Ile-Thiazolidide", (1999), 48(3): 385-389.	
e	CAW	<u>Pschyrembel</u> , Kininisches Wörterbuch 257, Auflage, (1994), 9 pages.	
Examiner:		Date: 3-20-06	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/4-CON	SERIAL NO. Not yet assigned
		APPLICANT(S): Demuth et al.	
		FILING DATE: December 11, 2003	ART UNIT: Not yet assigned
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
1	CAX	Snow et al., <u>Advances In Medicinal Chemistry</u> , "Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: A New Class of Immunosuppressive Agents", Vol. 3, (1995), p 149-177.	
	CAY	Thorens et al., <u>Diabetes</u> , "Glucagon-Like Peptide-I and the Control of Insulin Secretion in the Normal State and in NIDDM", (1993), 42:1219-1225.	
	CAZ	<u>Vidal</u> , (1993), 69 th Edition, p. 612-613.	
	CBA	Wakselman et al., "Inhibition of HIV-1 infection of CD 26 ⁺ but not CD 26 ⁻ cells by a potent cyclopeptidic inhibitor of the DPP IV activity of CD26", Abstract P 44 of the 24 th <u>European Peptide Symposium</u> , (1996).	
	CBB	Wettstein, J.G. et al. <u>Pharmacology & Therapeutics</u> , "Central Nervous System Pharmacology of Neuropeptide Y.", (1995), 65(3): 397-414.	
	CBC	Bergmeier, Stephen C., <u>Tetrahedron, Elsevier Science Ltd.</u> , "The Synthesis of Vicinal Amino Alcohols", Vol. 56, No. 17, (2000), pages 2561-2576.	
	CBD	Kowamoto et al., <u>Tetrahedron Asymmetry, Elsevier Science Ltd.</u> , "Enantioselective Synthesis of β -Hydroxy Amines and Aziridines Using Asymmetric Transfer Hydrogenation of α -Amido Ketones", Vol. 11, No. 16 (2000), pages 3257-3261.	
	CBE	Munglani R. et al., <u>Drugs, Adis International Ltd.</u> , At, "The Therapeutic Potential of Neuropeptide Y Analgesic, Anxiolytic and Antihypertensive", (1996) 52(3): 371-389.	
	CBF	Orskov, Cathrine et al., "Proglucagon Products in Plasma of Noninsulin-dependent Diabetics and Nondiabetic Controls in the Fasting State and after Oral Glucose and Intravenous Arginine" <u>J. Clin. Invest.</u> , Vol. 87, 1991, pages 415-423.	
	CBG	Reinhold, D. et al., <u>Journal of Neuroimmunology</u> , "Inhibitors of Dipeptidyl Peptidase IV/CD26 Suppress Activation of Human MBP-Specific CD4 + T Cell Clones", (1998) 87: 203-209.	
	CBH	Sengupta, et al., <u>Tetrahedron Letters, Elsevier Science Ltd.</u> , "Amino Acid Derived Morpholine Amides for Nucleophilic α -Amino Acylation Reactions: A New Synthetic Route to Enantiopure α -Amino Ketones", Vol. 40, No. 21 (1999), pages 4107-4110.	
	CBI	Stöckel-Maschek, A., et al., <u>Biochimica et Biophysica Acta</u> , "Thioxo Amino Acid Pyrrolidides and Thiazolidides: new Inhibitors of Proline Specific Peptidases", (2000) 1479: 15-31.	
	CBJ	Stryer, Lubert, <u>Biochemistry</u> , "Amino Acid Degradation and the Urea Cycle" (1975) pages 451-452.	
	CBK	Mentlein et al., <u>Eur. J. Biochem.</u> , Dipeptidyl-Peptidase IV Hydrolyses Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1(7-36)Amide, Peptide Histidine Methionine and is Responsible for Their Degradation in Human Serum. (1993), 214, pages 829-835.	
	CBL	Augustyns et al., <u>Eur. J. Med. Chem.</u> , "Pyrrolidides: Synthesis and Structure-Activity Relationship as Inhibitors of Dipeptidyl Peptidase IV", (1997), vol. 32, pages 301-309.	
	CBM	Wen-Tien Chen et al. "Seprase Complexes in Cellular Invasiveness", <u>Cancer and Metastasis Reviews</u> 22: 259-269, (2003).	
Examiner:		Date: 3-20-06	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/4-CON	SERIAL NO. Not yet assigned
		APPLICANT(S): Demuth et al.	
		FILING DATE: December 11, 2003	ART UNIT: Not yet assigned
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
9	CBN	Victor A. Gault et al., "Glucose-Dependent Insulinotropic Polypeptide Analogues and Their Therapeutic Potential for the Treatment of Obesity-Diabetes", <i>Biochemical and Biophysical Research Communications</i> 308: 207-213, (2003).	
1	CBO	Lader, Malcolm H., MD, "Assessment Methods and the Different Diagnosis of Anxiety", <i>Journal of Clinical Psychopharmacology</i> , (1981), Vol. 1, No. 6, pp. 342-349.	
2	CBP	Winslow, R., "Novartis Drug Alters Picture for Diabetes" <i>Wall Street Journal</i> , Wed., December 27, 2000, p. B2.	
3	CBQ	Ansorge, S., et al., "Membrane-bound peptidases of lymphocytes: Functional implications", <i>Biomed. Biochim. Acta</i> 50 (1991) 4-6, pp. 799-807.	
4	CBR	Dodge, R.W., et al., "Folding and Unfolding Kinetics of the Proline-to-Alanine Mutants of Bovine Pancreatic Ribonuclease A," <i>Biochemistry</i> 1996, 35, pp. 1548-1559.	
5	CBS	Hans-Ulrich Demuth, "Recent Developments in Inhibiting Cysteine and Serine Proteases", <i>J. Enzyme Inhibition</i> , 1990, Vol. 3, pp. 249-278.	
6	CBT	Gomez, S., et al., "Relationship between endo- and exopeptidases in a processing enzyme system: Activation of an endoprotease by the aminopeptidase B-like activity in somatostatin-28 convertase", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 85 pp. 5468-5472, August 1988.	
7	CBU	Hegen, M., et al., "The T Cell Triggering Molecule Tp103 is Associated with Dipeptidyl Aminopeptidase IV Activity," <i>The Journal of Immunology</i> , vol. 144, pp. 2908-2914, No. 8, April 15, 1990.	
8	CBV	Ishiura, S., et al., "Identification of a putative amyloid A4-generating enzyme as a prolyl endopeptidase," <i>Federation of European Biochemical Societies</i> , Vol. 260, No. 1, pp. 131-134, January 1990.	
9	CBW	Kräusslich, Hans-Georg, et al., "Viral Proteinases", <i>Ann. Rev. Biochem.</i> 1988, 57 pp. 701-754.	
10	CBX	Pederson, R.A., et al., "Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide", <i>Diabetes</i> , Vol. 47, August 1998 pp. 1253-1258.	
11	CBY	Vanhoof, G., et al., "Proline motifs in peptides and their biological processing", <i>The FASEB Journal</i> , Vol. 9, June 1995, pp. 736-744.	
12	CBZ	Walter, R., et al., "Proline Specific Endo- and Exopeptidases", <i>Molecular & Cellular Biochemistry</i> , Vol. 30, No. 2, April 18, 1980, pp. 111-127	
13	CBA	Kessler, Von Horst, "Konformation und biologische Wirkung von cyclischen Peptiden", <i>Angew. Chem.</i> 94 (1982) pp. 509-520.	
14	CCB	Kirschke, H. et al., "Proteinases 1: Lysosomal Cysteine Proteinases" <i>Protein Profile</i> , Vol. 2, Issue 14, 1995, pp. 1583-1634.	
15	CCC	Yaron, A., et al., "Proline-Dependent Structural and Biological Properties of Peptides and Proteins" <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 28(1), pp. 31-81 (1993).	
16	CCD	Vallee et al., "Larval Development of Tribolium Confusum in the Presence of Non-Naturally Occurring Amino Acids", Database CAPLUS on STN, Accession No.: 1963:75103, <i>Annales de l'ACFAS</i> (1962), 28, p. 26-27 (abstract).	
Examiner:		Date: 3-20-06	

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		ATTY. DOCKET NO. 20784/4-CON	SERIAL NO. Not yet assigned
		APPLICANT(S): Demuth et al.	
		FILING DATE: December 11, 2003	ART UNIT: Not yet assigned
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)			
①	CCE	Holst, J. et al., "Inhibition of the Activity of Dipeptidyl-Peptidase IV as a Treatment for Type 2 Diabetes", <i>Diabetes</i> , 47, 11, Health & Medical Complete pp. 1663-1670, Nov. 1998.	
Examiner: 		Date: 3-20-06	